Definium Therapeutics, Inc. (DFTX): Operating Income

Annual figures by period end, from SEC filings.

-$166.31M

Year ended 2025-12-31

-$227.54M

Trailing 12 months to 2026-06-30

2020-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$166.31M	n/m	2026-02-26, From 2025-01-01
2024-12-31	-$103.92M	n/m	2026-02-26, From 2024-01-01
2023-12-31	-$93.87M	n/m	2025-03-06, From 2023-01-01
2022-12-31	-$66.33M	n/m	2024-02-28, From 2022-01-01
2021-12-31	-$93.85M	n/m	2023-03-09, From 2021-01-01
2020-12-31	-$33.03M	n/a	2022-03-28, From 2020-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Medicinal Chemicals & Botanical Products), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Definium Therapeutics, Inc. (DFTX)	2025-12-31	-$166.31M	n/m
Jushi Holdings Inc. (JUSH)	2025-12-31	$4.85M	-55.3%
Glass House Brands Inc. (GLAS)	2025-12-31	-$16.53M	n/m
USANA Health Sciences Inc (USNA)	2026-01-03	$37.43M	-43.6%
Ascend Wellness Holdings, Inc. (AAWH)	2025-12-31	-$17.01M	n/m
Marimed Inc. (MRMD)	2025-12-31	-$2.82M	n/m
Cronos Group Inc. (CRON)	2025-12-31	-$17.39M	n/m
Cresco Labs Inc. (CRLBF)	2025-12-31	-$27.99M	n/m
Natural Alternatives International Inc (NAII)	2026-06-30	-$18.75M	n/m

Compare DFTX, JUSH, GLAS, USNA side by side · Screen every company in Medicinal Chemicals & Botanical Products ↗